Whoop
$ 9
$ 8,000,000,000
Angel investor
Common shares
<0.01%
The US$9 PPS and US$8B valuation are opportunity terms supplied to us, not independently verified company pricing. Confirm the share class, fully diluted share count, seller ownership and whether the price is on the same basis as the Series G preferred shares.
Summary
WHOOP is a wearable technology company that combines a screenless sensor with a mobile application and paid membership.
Unlike conventional smartwatches, WHOOP focuses on continuous physiological monitoring rather than notifications, calls or displaying information on a screen.
Its value proposition is simple: help users understand how their body responds to exercise, sleep, stress, nutrition and everyday behaviour.
The platform uses biometric data and personalised analytics to recommend when users should train harder, recover or adjust their lifestyle.
The Business
A. WHOOP 5.0
Screenless wearable that continuously tracks heart rate, heart-rate variability, sleep, respiratory rate, activity and other physiological metrics.
B. WHOOP MG
Medical-grade hardware with additional health features, including ECG readings and irregular heart rhythm notifications where available.
C. WHOOP App and AI Coach
Provides personalised coaching, sleep and recovery scores, strain analysis, stress monitoring, health trends and behaviour insights.
D. WHOOP Advanced Labs
Adds blood testing and health insights to the wearable platform, extending the business beyond daily fitness monitoring.
E. WHOOP Unite
Business and organisational offering for corporate wellness, teams and health-focused organisations.
5. Membership model and pricing
WHOOP follows a subscription-led model. Hardware is bundled with a membership, creating recurring revenue and an ongoing relationship with the customer.
Membership | US annual price | Main features |
|---|---|---|
WHOOP One | US$199 | Sleep, strain, recovery and core fitness insights |
WHOOP Peak | US$239 | Additional health monitoring, stress and Healthspan |
WHOOP Life | US$359 | Medical-grade hardware, ECG and additional health features |
Prices and feature availability vary by region and membership terms.
Why this model matters: Unlike a one-time hardware sale, membership renewals can generate recurring revenue, improve customer lifetime value and create opportunities to sell additional health services.
6. Market opportunity
Market | Opportunity |
|---|---|
Fitness wearables | Continuous tracking of exercise and activity |
Preventive health | Early identification of changes in health metrics |
Sleep technology | Sleep quality, duration and recovery insights |
Corporate wellness | Health and performance monitoring for organisations |
Sports performance | Training optimisation and athlete recovery |
Digital health | Personalised insights using longitudinal biometric data |
Diagnostics | Integration of blood testing and clinical services |
Market drivers
Rising consumer focus on health and longevity.
Growing adoption of wearable health devices.
Demand for personalised fitness and wellness recommendations.
Increasing use of AI to interpret health data.
Shift from reactive healthcare towards preventive monitoring.
7. Customers, partnerships and ecosystem
WHOOP has built a strong brand among athletes, fitness enthusiasts and health-conscious consumers.
Notable strategic relationships include:
Abbott — strategic investor and healthcare technology partner.
Mayo Clinic — investor in the Series G round, bringing clinical and healthcare expertise.
Quest Diagnostics — blood-testing ecosystem associated with WHOOP Advanced Labs.
GRAIL — partnership ecosystem for advanced cancer screening access.
HealthEx — health-record connectivity.
Athlete investors and ambassadors — including Cristiano Ronaldo, LeBron James and Rory McIlroy.
These relationships support WHOOP's positioning as a broader health platform, rather than simply a fitness tracker manufacturer.
8. Financial information
WHOOP does not publicly disclose a complete set of audited financial statements. Its March 2026 funding announcement provides useful operating indicators.Disclosed operating indicators
Indicator | Reported figure |
|---|---|
Global members | 2.5M+ |
2025 bookings growth | 103% YoY |
2025 exit bookings run rate | US$1.1B |
2025 cash flow | Cash-flow positive |
Physiological data processed | 24B+ hours |
Planned global hiring in 2026 | 600+ roles |
Financial interpretation: The US$1.1B figure is a bookings run rate, not necessarily recognised revenue or ARR. It should not be inserted as reported revenue in a financial model without a reconciliation. EBITDA, gross margin and CAPEX remain undisclosed.
The Market
Funding and valuation history
Date | Round | Amount | Valuation |
|---|---|---|---|
October 2020 | Series E | US$100M | US$1.2B |
August 2021 | Series F | ~US$200M | US$3.6B |
March 2026 | Series G | US$575M | US$10.1B |
The Series G round was led by Collaborative Fund, with participation from QIA, Mubadala, Abbott, Mayo Clinic, Macquarie Capital, IVP and other institutional and individual investors.
The latest publicly announced financing valuation of US$10.1B provides the primary valuation benchmark for evaluating the offered US$8B secondary opportunity.
Financial Data
| Financials | Last 12 Months |
|---|---|
| Revenue | $0 |
Growth Roadmap
International expansion: Grow membership across Europe, the GCC, Latin America and Asia.
Medical and health features: Expand the product from fitness tracking into broader health monitoring.
AI-powered coaching: Use accumulated biometric data to improve personalised recommendations.
Advanced diagnostics: Expand blood testing and clinical service integrations.
Enterprise growth: Develop WHOOP Unite for corporate and organisational customers.
Health platform strategy: Build a unified platform connecting wearable data, diagnostics and health records.
WHOOP's stated Series G strategy includes global expansion, product development and investment in its personalised health platform.
11. Competitive landscape
Competitor | Positioning |
|---|---|
Oura | Smart rings focused on sleep, recovery and health |
Apple | Apple Watch health and fitness ecosystem |
Garmin | Sports, fitness and performance wearables |
Fitbit | Consumer fitness and health tracking |
Samsung | Galaxy Watch and health monitoring |
Ultrahuman | Smart rings and metabolic health monitoring |
WHOOP's differentiation
Screenless, distraction-free design.
Strong focus on recovery, sleep and physiological performance.
Subscription-based business model.
Personalised coaching and longitudinal biometric data.
Premium positioning among athletes and health-conscious consumers.
12. Additional transaction information — internal use
Entry valuation analysis
Indicative secondary valuation
US$8.0B
Latest Series G valuation
US$10.1B
Indicative discount
Offered PPS
US$9.00
Fee economics
The opportunity is quoted as 5 / 0 / 0.
If the first 5% is a transaction fee charged on the investment amount:
Investment | Illustrative 5% fee |
|---|---|
US$250K | US$12,500 |
US$500K | US$25,000 |
US$1M | US$50,000 |
US$2M | US$100,000 |
US$5M | US$250,000 |
Fee payer, calculation base and whether the fee is added to the US$9 PPS must be confirmed before quoting all-in investor pricing.
13. Key investment positives and risks
Positives
Established global wearable brand.
2.5M+ members and strong subscription growth.
Cash-flow-positive operations reported for 2025.
US$1.1B bookings run rate at the end of 2025.
Strong institutional and strategic investor participation.
Expansion into diagnostics, preventive health and AI-driven insights.
Potential secondary entry below the latest disclosed financing valuation.
Risks
US$8B is still a substantial valuation.
Hardware manufacturing, inventory and supply-chain exposure.
Subscription churn and customer acquisition costs.
Competition from Apple, Oura and Garmin.
Medical-feature regulatory and product-claim risks.
Limited publicly available audited financial information.
Share transfer restrictions and potential illiquidity before an IPO.
Uploaded Documents
No documents uploaded
$ 9
$ 8,000,000,000
Angel investor
Common shares
<0.01%
The US$9 PPS and US$8B valuation are opportunity terms supplied to us, not independently verified company pricing. Confirm the share class, fully diluted share count, seller ownership and whether the price is on the same basis as the Series G preferred shares.
© 2026 by AngelLinx. All rights reserved.